Ultralife (ULBI) Projected to Post Earnings on Thursday

Ultralife (NASDAQ:ULBI) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, July 24th. Analysts expect Ultralife to post earnings of $0.14 per share and revenue of $51.00 million for the quarter.

Ultralife (NASDAQ:ULBI) last posted its quarterly earnings data on Friday, May 9th. The technology company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.02). The business had revenue of $50.75 million during the quarter, compared to analyst estimates of $54.50 million. Ultralife had a return on equity of 4.61% and a net margin of 3.05%. During the same period in the prior year, the firm posted $0.21 EPS.

Ultralife Price Performance

Ultralife stock opened at $8.60 on Thursday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.70 and a current ratio of 3.22. The firm has a market cap of $143.02 million, a P/E ratio of 26.88 and a beta of 1.00. The business’s fifty day moving average is $7.37 and its two-hundred day moving average is $6.56. Ultralife has a 52 week low of $4.07 and a 52 week high of $12.40.

Insider Buying and Selling at Ultralife

In other news, Director Bradford T. Whitmore purchased 16,063 shares of the business’s stock in a transaction dated Wednesday, May 14th. The shares were acquired at an average price of $5.47 per share, with a total value of $87,864.61. Following the completion of the purchase, the director directly owned 1,045,947 shares of the company’s stock, valued at $5,721,330.09. The trade was a 1.56% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas Louis Saeli bought 5,000 shares of the business’s stock in a transaction on Wednesday, May 14th. The stock was bought at an average cost of $5.44 per share, for a total transaction of $27,200.00. Following the purchase, the director directly owned 85,000 shares of the company’s stock, valued at approximately $462,400. This trade represents a 6.25% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 47,140 shares of company stock worth $256,355 in the last ninety days. 40.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ultralife

An institutional investor recently raised its position in Ultralife stock. Jones Financial Companies Lllp raised its stake in Ultralife Corporation (NASDAQ:ULBI) by 1,428.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,287 shares of the technology company’s stock after buying an additional 14,287 shares during the quarter. Jones Financial Companies Lllp owned 0.09% of Ultralife worth $82,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 30.68% of the company’s stock.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Ultralife from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 6th.

Ultralife Company Profile

Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.